GID8

Across TCGA pan-cancer cohorts, GID8 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GID8 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GID8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GID8 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LSCC, and OV are the cancer types where GID8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.365	0.715	<.001	17	view →
LSCC	OS	Median	All	1.000	0.925	.014	8	view →
OV	DFS	Median	All	0.847	1.000	.021	4	view →
UCEC	DFS	Median	All	0.928	0.793	.037	4	view →
HNSC	OS	Median	IV	0.827	0.594	.018	3	view →
LUAD	OS	Quartile	II,III,IV	0.243	0.871	.025	2	view →
CCRCC	DFS	Quartile	III,IV	0.495	0.779	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GID8–PDAC (OS)

Open the PDAC breakdown →